Zinc may be the ideal ingredient for bioabsorbable stents, new research from Michigan Technology University concludes.
Boston Scientific's ongoing stent patent fight against a smaller rival has taken a turn for the worse in a German court. OrbusNeich can now prevent the Massachusetts medical device giant from marketing certain stent models in Germany, thanks to a preliminary injunction that affirmed they violate two of its patents.
Altura Medical has grabbed $6 million in new venture equity financing, according to a regulatory filing.
Cook Medical is working to get its Zilver Vena stent FDA approved, launching a global trial to study the device's benefits for patients with iliofemoral venous outflow obstruction.
A civil trial has begun for a Maryland cardiologist facing multiple lawsuits from patients alleging they were subjected to stent procedures that weren't ultimately needed.
Abbott Laboratories has laid off another 450 employees from its vascular division, this time targeting a San Diego-area plant that manufactures stents.
Even as stent manufacturers are bumping into each other in Europe vying for business, Boston Scientific ($BSX) is bringing yet another entry into the competition: The Promus Premier.
Indian stent makers are becoming increasingly viable competitors in international markets, adding another layer to an industry already crowded with a number of players.
Tryton Medical has pulled in $24 million in equity financing, looping all its investors to pitch in as it prepares to seek FDA approval for its Side Branch Stent to treat bifurcated lesions.
Biotronik has kicked off a multi-center investigational device trial for its Pulsar-18, targeting U.S. approval for its self-expanding device.